Patents by Inventor Julie Nicole Hamblin

Julie Nicole Hamblin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230212131
    Abstract: The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: June 9, 2021
    Publication date: July 6, 2023
    Applicant: Anima Biotech Inc.
    Inventors: David William SHEPPARD, Jason Paul TIERNEY, Aviad MANDABI, Wolfgang SCHMIDT, Stefano LEVANTO, Julie Nicole HAMBLIN, Richard James BULL, Iris ALROY, Wissam MANSOUR, Moty KLEPFISH, Yaode WANG, Haitang LI
  • COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230150980
    Abstract: The present invention relates to novel Collagen I translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: April 21, 2021
    Publication date: May 18, 2023
    Applicant: Anima Biotech Inc.
    Inventors: David William SHEPPARD, Jason Paul TIERNEY, Aviad MANDABI, Wolfgang SCHMIDT, Stefano LEVANTO, Julie Nicole HAMBLIN, Richard James BULL, Iris ALROY, Wissam MANSOUR, Moty KLEPFISH, Yaode WANG, Haitang Ll, Stephen David PENROSE
  • COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230116201
    Abstract: The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: January 28, 2021
    Publication date: April 13, 2023
    Applicant: Anima Biotech Inc.
    Inventors: David William SHEPPARD, Jason Paul TIERNEY, Wolfgang SCHMIDT, William Rameshchandra ESMIEU, Julie Nicole HAMBLIN, Richard James BULL, Iris ALROY, Wissam MANSOUR, Moty KLEPFISH, Aviad MANDABI
  • Oxepinopyrazole derivatives as inhibitors of P13-kinase activity
    Patent number: 11555040
    Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: January 17, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andrew Baxter, Sophie Marie Bertrand, Matthew Campbell, Kenneth David Down, Curt Dale Haffner, Julie Nicole Hamblin, Zoe Alicia Henley, William Henry Miller, Eric Philippe Andre Talbot, Jonathan Andrew Taylor
  • CHEMICAL COMPOUNDS
    Publication number: 20220324875
    Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: April 16, 2018
    Publication date: October 13, 2022
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Andrew BAXTER, Sophie Marie BERTRAND, Matthew CAMPBELL, Kenneth David DOWN, Curt Dale HAFFNER, Julie Nicole HAMBLIN, Zoe Alicia HENLEY, William Henry MILLER, Eric Philippe Andre TALBOT, Jonathan Andrew TAYLOR
  • ENZYME INHIBITORS
    Publication number: 20220298138
    Abstract: The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.
    Type: Application
    Filed: August 21, 2019
    Publication date: September 22, 2022
    Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Sally Louise MARSH, Alessandro MAZZACANI, David Philip ROOKER, Michael John STOCKS, Andrew Peter CRIDLAND, Emanuela GANCIA, Julie Nicole HAMBLIN, Paul Stuart HINCHLIFFE, Stefano LEVANTO, Terence Aaron PANCHAL, Iain Robert MILLER
  • Compounds
    Patent number: 10946025
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: March 16, 2021
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Chemical compounds
    Patent number: 10793559
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 6, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • NOVEL COMPOUNDS
    Publication number: 20200206237
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Compounds
    Patent number: 10624898
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: April 21, 2020
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • CHEMICAL COMPOUNDS
    Publication number: 20200071311
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 5, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew ANDERSON, Nicholas Paul BARTON, Sebastien Andre CAMPOS, Edward Paul CANNONS, Anthony William James COOPER, Kenneth David DOWN, Kevin James DOYLE, Julie Nicole HAMBLIN, Graham George Adam INGLIS, Armelle LE GALL, Vipulkumar Kantibhai PATEL, Simon PEACE, Andrew SHARPE, Gemma Victoria WHITE
  • NOVEL COMPOUNDS
    Publication number: 20190328744
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 31, 2019
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • Chemical compounds
    Patent number: 10457674
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: October 29, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • Compounds
    Patent number: 10383879
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 20, 2019
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • NOVEL COMPOUNDS
    Publication number: 20190175608
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: February 20, 2019
    Publication date: June 13, 2019
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • CHEMICAL COMPOUNDS
    Publication number: 20190040051
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 7, 2019
    Inventors: Niall Andrew ANDERSON, Nicholas Paul BARTON, Sebastien Andre CAMPOS, Edward Paul CANNONS, Anthony William James COOPER, Kenneth David DOWN, Kevin James DOYLE, Julie Nicole HAMBLIN, Graham George Adam INGLIS, Armelle LE GALL, Vipulkumar Kantibhai PATEL, Simon PEACE, Andrew SHARPE, Gemma Victoria WHITE
  • NOVEL COMPOUNDS
    Publication number: 20180325911
    Abstract: The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: May 16, 2018
    Publication date: November 15, 2018
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • NOVEL COMPOUNDS
    Publication number: 20170157136
    Abstract: The invention is directed to methods of treatment using compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • NOVEL COMPOUNDS
    Publication number: 20170015656
    Abstract: The invention is directed to certain novel compounds. Specifically, crystalline forms of N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide and crystalline 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole, along with salts thereof.
    Type: Application
    Filed: August 2, 2016
    Publication date: January 19, 2017
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR
  • P13K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE
    Publication number: 20160263109
    Abstract: The present invention is directed to compounds and pharmaceutically acceptable salts thereof which are inhibitors of the activity or function of the phosphoinositide 3?OH kinase family (hereinafter PI3K) for use in the treatment or prevention of respiratory infections, the treatment of airway damage, and/or the prevention of airway injury in patients.
    Type: Application
    Filed: October 15, 2014
    Publication date: September 15, 2016
    Inventors: Augustin AMOUR, Julie Nicole HAMBLIN, Edith HESSEL, David MICHALOVICH, Srividya SRISKANTHARAJAH